You are here: Industry Insights > abrocitinib

News List

Patients gain early access to Pfizer's atopic dermatitis drug pharmatimes
February 04, 2021
People living in the UK with severe atopic dermatitis are to be given early access to Pfizer's abrocitinib following a green light by the Medicines and Healthcare products Regulatory Agency (MHRA).
Pfizer’s abrocitinib scores another phase III win in atopic dermatitis pharmatimes
November 12, 2020
Pfizer’s investigational oral Janus kinase 1 (JAK1) inhibitor abrocitinib has scored positive top-line results in a phase III atopic dermatitis trial.
FDA grants priority review and EMA accepts regulatory submission for Pfizer’s abrocitinib pharmaceutical-business-review
October 30, 2020
Pfizer announced that the U.S. Food and Drug Administration (FDA) accepted for filing and granted Priority Review designation to the company’s New Drug Application (NDA) for abrocitinib (100mg and 200mg) ...
Pfizer announces positive top-line results from JADE TEEN trial of abrocitinib in adolescents with moderate-to-severe atopic dermatitis pharmaceutical-business-review
June 17, 2020
Pfizer announced positive top-line results from the Phase 3 JADE TEEN study of abrocitinib, an investigational oral once-daily Janus kinase 1 (JAK1) inhibitor.
Pfizer’s abrocitinib hits endpoints in late-stage atopic dermatitis study pharmatimes
March 23, 2020
Pfizer has revealed that its investigational Janus kinase 1 (JAK1) inhibitor, abrocitinib, has met its co-primary efficacy endpoints in a Phase III moderate to severe atopic dermatitis trial.
Pfizer's abrocitinib smashes primary and secondary endpoints at Phase 3 in atopic dermatitis pharmafile
May 17, 2019
Pfizer has lifted the curtain on new Phase 3 data for its Janus kinase 1 (JAK1) inhibitor abrocitinib, revealing that the therapy met all of its co-primary and secondary endpoints in the treatment of moderate to severe atopic dermatitis (AD) in patients a